RIGL
RIGEL PHARMACEUTICALS INC
+1.59 (+3.57%)46.07USD35.7K成交股數861M市值2.7本益比(近四季)3.1股價營收比-22.6%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 78.7M+48% | 58.8M+2% | 69.5M+26% | 102M+176% | 53.3M+81% | 57.6M+105% | 55.3M+106% | 36.8M+41% | 29.5M | 28.1M | 26.9M | 26.1M |
| 營業成本 | 8.5M | 4.6M | 4.8M | 4.5M | 4.4M | 5.8M | 8.0M | 2.8M | 2.0M | 1.3M | 1.1M | 977K |
| 毛利 | 70.2M+43% | 54.2M+5% | 64.7M+37% | 97.2M+186% | 48.9M+78% | 51.8M+93% | 47.3M+83% | 34.0M+36% | 27.5M | 26.9M | 25.8M | 25.1M |
| 毛利率 | 89.2% | 92.2% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 95.5% | 96.0% | 96.3% |
| 研發費用 | 14.0M | 11.7M | 7.4M | 6.8M | 8.4M | 5.6M | 6.2M | 5.5M | 6.0M | 6.5M | 4.8M | 10.1M |
| 銷售管理費用 | 32.6M | 30.7M | 28.9M | 29.3M | 27.7M | 29.5M | 27.0M | 28.0M | 28.4M | 24.9M | 26.3M | 27.7M |
| 營業利益 | 23.6M+85% | 11.9M-29% | 28.4M+102% | 61.1M+13570% | 12.8M-283% | 16.7M-473% | 14.1M-367% | 447K-104% | −7.0M | −4.5M | −5.3M | −12.7M |
| 營業利益率 | 30.0% | 20.2% | 40.9% | 60.1% | 23.9% | 28.9% | 25.4% | 1.2% | -23.6% | -15.9% | -19.6% | -48.8% |
| 稅後淨利 | 17.3M+51% | 8.7M-40% | 27.9M+125% | 59.6M-5888% | 11.4M-239% | 14.3M-352% | 12.4M-288% | −1.0M-92% | −8.2M | −5.7M | −6.6M | −13.5M |
| 淨利率 | 22.0% | 14.7% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | -2.8% | -27.9% | -20.2% | -24.5% | -51.9% |
| 稀釋 EPS | 0.88+40% | 0.44-46% | 1.46+109% | 3.28-5567% | 0.63-234% | 0.82-348% | 0.70-284% | -0.06-25% | -0.47 | -0.33 | -0.38 | -0.08 |
| 稀釋股數 | 19.6M | 19.7M | 19.2M | 18.2M | 18.2M | 17.7M | 17.6M | 17.5M | 17.5M | 17.4M | 17.4M | 174M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 60.8M | 24.4M | 48.5M | 53.4M | 45.7M | 56.7M | 51.7M | 36.1M | 25.6M | 45.4M | 48.8M | 40.3M |
| 應收帳款 | 56.0M | 49.9M | 45.9M | 39.9M | 41.5M | 41.6M | 30.6M | 28.9M | 27.5M | 23.5M | 20.8M | 29.4M |
| 存貨 | 14.4M | 11.7M | 13.3M | 10.4M | 4.7M | 6.0M | 4.8M | 8.1M | 6.6M | 6.1M | 10.8M | 11.1M |
| 總資產 | 521M | 505M | 243M | 207M | 176M | 164M | 139M | 128M | 127M | 115M | 117M | 124M |
| 有息負債 | – | 45.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M | 60.0M |
| 總負債 | 95.6M | 105M | 125M | 125M | 157M | 161M | 154M | 158M | 158M | 147M | 145M | 148M |
| 股東權益 | 425M | 400M | 118M | 81.9M | 18.6M | 3.3M | −14.6M | −29.9M | −31.7M | −31.8M | −28.1M | −24.3M |
| 負債比 | 18.4% | 20.8% | 51.5% | 60.4% | 89.4% | 98.0% | 110.5% | 123.3% | 125.0% | 127.6% | 124.0% | 119.6% |
| 淨現金(現金 − 有息負債) | – | −20.6M | −11.5M | −6.6M | −14.3M | −3.3M | −8.3M | −23.9M | −34.4M | −14.6M | −11.2M | −19.7M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 2.7M | – | – | −893K-82% | – | – | – | −5.0M | – | – | −4.1M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | 597K | – | – | 604K | – | – | – | 400K | – | – | 357K |
| 買回庫藏股 | – | 3.7M | – | – | 0.00 | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 294M
| Single Reportable | 294M | 100.0% | +64.1% |
|---|
產品／服務2025 年度 · 294M
| 產品 | 232M | 78.8% | +60.1% |
|---|---|---|---|
| Release Of Share Cost Liability | 40.0M | 13.6% | – |
| Royalty Delivery Of Drug Supplies And Others | 19.1M | 6.5% | -6.5% |
| Development Milestones | 3.0M | 1.0% | – |
| Government Contract | 265K | 0.1% | – |
| Gross Product 小計 | 310M | 105.3% | +47.7% |
| Contract Revenues From Collaborations 小計 | 62.0M | 21.1% | +80.5% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 294M | +64.1% | 367M | 124.7% | 19.48 | – |
| FY2024 | 179M | +53.4% | 17.5M | 9.8% | 0.99 | – |
| FY2023 | 117M | -2.8% | −25.1M | -21.5% | -1.44 | – |
| FY2022 | 120M | -19.4% | −58.6M | -48.7% | -3.44 | −74.2M |
| FY2021 | 149M | +37.4% | −17.9M | -12.0% | -0.11 | 5.3M |
| FY2020 | 109M | +83.2% | −29.7M | -27.4% | -0.18 | −53.4M |
| FY2019 | 59.3M | +33.2% | −66.9M | -112.8% | -0.40 | −43.0M |
| FY2018 | 44.5M | – | −70.5M | -158.3% | -0.44 | −59.9M |